130 related articles for article (PubMed ID: 2013446)
1. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
[TBL] [Abstract][Full Text] [Related]
2. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
Willemse PH; Sleijfer DT; de Vries EG; Boonstra H; Bouma J; Mulder NH
Eur J Cancer; 1992; 28(2-3):479-81. PubMed ID: 1591067
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.
Nardi M; Cognetti F; Pollera CF; Giulia MD; Lombardi A; Atlante G; Calabresi F
J Clin Oncol; 1990 Jun; 8(6):1036-41. PubMed ID: 2189953
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.
Markman M; Berek JS; Blessing JA; McGuire WP; Bell J; Homesley HD
Gynecol Oncol; 1992 Apr; 45(1):3-8. PubMed ID: 1601332
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P
J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer.
Pfeiffer P; Bennedbaek O; Bertelsen K
Gynecol Oncol; 1990 Mar; 36(3):306-11. PubMed ID: 2180794
[TBL] [Abstract][Full Text] [Related]
7. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
Kirmani S; Lucas WE; Kim S; Goel R; McVey L; Morris J; Howell SB
J Clin Oncol; 1991 Apr; 9(4):649-57. PubMed ID: 2066761
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
Lund B; Hansen OP; Hansen HH; Hansen M
Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
[TBL] [Abstract][Full Text] [Related]
11. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal chemotherapy with cisplatin and melphalan.
Piccart MJ; Abrams J; Dodion PF; Crespeigne N; Sculier JP; Pector JC; Finet C; Nouwijnck C; Bondue H; Atassi G
J Natl Cancer Inst; 1988 Sep; 80(14):1118-24. PubMed ID: 3411624
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
[TBL] [Abstract][Full Text] [Related]
14. Human lymphoblastoid interferon (IFN-alpha-N1) plus doxorubicin, cyclophosphamide, and cisplatin in the treatment of advanced epithelial ovarian malignancies. A phase I-II study of the Gynecologic Oncology Group.
DiSaia PJ; Gillette P
Am J Clin Oncol; 1991 Feb; 14(1):71-4. PubMed ID: 1987744
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
Gasparini G; Dal Fior S; Pozza F; Panizzoni GA; Favretto S; Von Hoff DD
Invest New Drugs; 1991 Aug; 9(3):245-52. PubMed ID: 1783524
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
[TBL] [Abstract][Full Text] [Related]
17. Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy.
de Gramont A; Demuynck B; Louvet C; Gonzalez-Canali G; Varette C; Pigné A; Marpeau L; Herbulot P; Lagadec B; Cady J
Am J Clin Oncol; 1992 Feb; 15(1):7-11. PubMed ID: 1550083
[TBL] [Abstract][Full Text] [Related]
18. Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies.
Sandles LG; Freedman RS; Raber MN; Kavanagh J; Edwards CL; Scott WR; Wharton JT
Gynecol Oncol; 1990 Nov; 39(2):139-45. PubMed ID: 2121628
[TBL] [Abstract][Full Text] [Related]
19. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
